Correction to: Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study (Cancer Med., (2024), 13, 15, (e7408), 10.1002/cam4.7408)

Authors
Category Primary study
JournalCancer Medicine
Year 2024
Shao Z, et al., Cancer Med. 2024 Aug;13(15):e7408. https://doi.org/10.1002/cam4.7408. PMID: 39136200; PMCID: PMC11320080 We requested post-publication to add the following line after the first line in the acknowledgment section: We also thank DMC chair Prof. Xichun Hu, DMC member Prof. Jin Zhang, Prof. Shusen Wang, Prof. Renbing Liu, and Prof. Chen Yao for their contributions to the trial. We apologize for this error.
Epistemonikos ID: 85286a20f7fbf719b9137fd7031e823a48905885
First added on: Sep 15, 2024